Abstract: The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by formula I: or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.

Abstract: The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by formula I: or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.

Abstract: The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by formula I: or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.

Abstract: The invention generally relates to the field of nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to new substituted-heterocyclic azole compounds, the synthesis and use of these compounds and their pharmaceutical compositions, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity such as in treating cancer and other neoplastic disorders, inflammatory diseases, disorders of abnormal tissue growth and fibrosis including cardiomyopathy, pulmonary fibrosis, hepatic fibrosis, glomerulonephritis, and other renal disorders, and for the treatment of viral infections (both acute and chronic).

Abstract: The invention generally relates to nuclear transport modulators, e.g CRM1 inhibitors, and more particularly to a compound represented by formula (I): or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula (I), or a pharmaceutically acceptable salt or composition thereof, e.g, in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.

Abstract: The invention generally relates to nuclear transport modulators, e.g CRM1 inhibitors, and more particularly to a compound represented by formula (I): or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula (I), or a pharmaceutically acceptable salt or composition thereof, e.g, in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.

Abstract: The present disclosure provides a system, apparatus and method to transport data across a network node, as part of a network infrastructure of an optical transmission system. According to the various embodiments of the disclosure, a base architecture is provided which includes interconnectivity providing high throughput, while mitigating factors which may lead to signal loss or signal degradation. The base architecture is easily expandable to accommodate additional traffic.

Abstract: The invention generally relates to the field of nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to new substituted-heterocyclic azole compounds, the synthesis and use of these compounds and their pharmaceutical compositions, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity such as in treating cancer and other neoplastic disorders, inflammatory diseases, disorders of abnormal tissue growth and fibrosis including cardiomyopathy, pulmonary fibrosis, hepatic fibrosis, glomerulonephritis, and other renal disorders, and for the treatment of viral infections (both acute and chronic).

Abstract: The invention generally relates to the field of nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to new substituted-heterocyclic azole compounds, the synthesis and use of these compounds and their pharmaceutical compositions, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity such as in treating cancer and other neoplastic disorders, inflammatory diseases, disorders of abnormal tissue growth and fibrosis including cardiomyopathy, pulmonary fibrosis, hepatic fibrosis, glomerulonephritis, and other renal disorders, and for the treatment of viral infections (both acute and chronic).

Abstract: Embodiments of the present invention provide arrays of electrical circuits having one or more chirped elements or components for providing output signals to corresponding arrays of electro-optic devices. Certain embodiments of the present invention include a plurality of modulator driver circuits, each of the plurality of driver circuits configured to be substantially identical to each other and provide a corresponding one of a plurality of modulator drive signals to a respective one of a plurality of electro-optic modulators, each of the plurality of modulator driver circuits being chirped to provide a desired output to the corresponding electro-optic modulator for enhanced operation.

Abstract: The present disclosure provides a system, apparatus and method to transport data across a network node, as part of a network infrastructure of an optical transmission system. According to the various embodiments of the disclosure, a base architecture is provided which includes interconnectivity providing high throughput, while mitigating factors which may lead to signal loss or signal degradation. The base architecture is easily expandable to accommodate additional traffic.

Abstract: The invention generally relates to the field of nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to new substituted-heterocyclic azole compounds, the synthesis and use of these compounds and their pharmaceutical compositions, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity such as in treating cancer and other neoplastic disorders, inflammatory diseases, disorders of abnormal tissue growth and fibrosis including cardiomyopathy, pulmonary fibrosis, hepatic fibrosis, glomerulonephritis, and other renal disorders, and for the treatment of viral infections (both acute and chronic).

Abstract: A modulator drive circuit provides a modulator drive signal to modulate an optical signal for transport across a network infrastructure. The modulator drive circuit powered by an adjustable voltage source, such that the modulator drive signal is generated from a data signal and the adjustable voltage source, an AC component of the modulator drive signal being derived from the data signal while a DC component of the modulator drive signal being derived from the adjustable voltage source. An array of such modulator drive circuits are provided on a single substrate.

Abstract: Embodiments of the present invention provide arrays of electrical circuits having one or more chirped elements or components for providing output signals to corresponding arrays of electro-optic devices. Certain embodiments of the present invention include a plurality of modulator driver circuits, each of the plurality of driver circuits configured to be substantially identical to each other and provide a corresponding one of a plurality of modulator drive signals to a respective one of a plurality of electro-optic modulators, each of the plurality of modulator driver circuits being chirped to provide a desired output to the corresponding electro-optic modulator for enhanced operation.

Abstract: Chromatic dispersion is determined based on the arrival times of different frames of data in a wavelength division multiplexed (WDM) system having an optical communication link. Namely, a first frame is transmitted on a first optical channel, which is supplied to the optical communication link. A second frame is then transmitted on a second optical channel and the transmission time difference between the two frames is obtained. At a receive end, the difference in arrival times of the two frames is measured to obtain a relative time delay between the first and second frames and used to determine a chromatic dispersion.

Abstract: Chromatic dispersion is determined based on the arrival times of different frames of data in a wavelength division multiplexed (WDM) system having an optical communication link. Namely, a first frame is transmitted on a first optical channel, which is supplied to the optical communication link. A second frame is then transmitted on a second optical channel and the transmission time difference between the two frames is obtained. At a receive end, the difference in arrival times of the two frames is measured to obtain a relative time delay between the first and second frames. The relative time delay is the sum of the transmission time difference and the propagation time difference (the time difference attributable to chromatic dispersion) between the two frames. Thus, by subtracting the transmission time difference from the relative time delay, the propagation time difference can be obtained.

Abstract: A method for generating an electron beam includes prescribing a location, and generating an envelope of electrons, the envelope having a waist, wherein the generating is performed such that the waist of the envelope is at or adjacent to the prescribed location. A device for generating an electron beam includes a gun source for generating electrons, and a plurality of electromagnetic cavities coupled in series to form a body, the electromagnetic cavities configured to accelerate at least some of the electrons to create a beam of electrons at an energy level having a value between 5 MeV and 20 MeV, the beam of electrons having a cross sectional dimension that is 0.02 ? (or 2 mm) or less.

Abstract: Compositions and methods disclosed herein capitalize on the discovery that rejection of a tissue graft can be inhibited using a CD40:CD154 binding interrupter, either alone or in combination with another immunomodulator or immunosuppressor. An advantageous, synergistic combination includes a CD40:CD154 binding interrupter and a CD28 signaling interrupter. An exemplary CD40:CD154 binding interrupter is an anti-CD154 monoclonal antibody, such as an antibody having the antigen-specific binding characteristics of the 5c8 monoclonal antibody. An exemplary CD28 signaling interrupter is a CTLA4-Ig fusion protein. The disclosed compositions and methods unexpectedly can be used to prolong survival of grafted tissue in a recipient host, to reverse acute graft rejection, and to attenuate immunological consequences of the failure of grafted tissue.

Abstract: A method for generating an electron beam includes prescribing a location, and generating an envelope of electrons, the envelope having a waist, wherein the generating is performed such that the waist of the envelope is at or adjacent to the prescribed location. A device for generating an electron beam includes a gun source for generating electrons, and a plurality of electromagnetic cavities coupled in series to form a body, the electromagnetic cavities configured to accelerate at least some of the electrons to create a beam of electrons at an energy level having a value between 5 MeV and 20 MeV, the beam of electrons having a cross sectional dimension that is 0.02 ? (or 2 mm) or less.

Abstract: A system for reducing the cost of network managment by using a proxy agent and subchannel communications so fewer SNMP licenses and fewer protocol stacks are needed. Subchannel communication is achieved in a plurality of different embodiments. Embodiments having single subchannel transceivers, multiple transceivers, single multiplexer and multiple multiplexers are disclosed. An NMS process using routing table CRC to automatically detect when the NMS topology information is incorrect and automated topology discovery is disclosed. A process for automated discovery of redundant cables during automated topology discovery is disclosed.